Business Context and Reporting Period
Company: REGENXBIO Inc. (RGNX)
Filing Type: Form 8-K (Current Report)
Date of Report: August 18, 2025
Event: Announcement of a PDUFA date extension by the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for clemidsogene lanparvovec (RGX-121).
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a regulatory event. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The primary material change reported is the regulatory timeline for the Company's lead asset:
- Asset: Clemidsogene lanparvovec (RGX-121).
- Indication: Treatment of Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome.
- Change: The FDA extended the Prescription Drug User Fee Act (PDUFA) action date.
- Previous Date: November 9, 2025.
- New Date: February 8, 2026.
- Reason: To allow for the review of additional data.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) but does not include specific management commentary, financial guidance, or updated operational outlook within the text of the 8-K itself.
Risks and Contingencies: The extension of the PDUFA date introduces a delay in the potential accelerated approval of RGX-121. The need for additional data review implies the FDA requires further information before making a decision, which is a standard regulatory contingency but impacts the commercialization timeline.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for specific details on the "additional data" requested by the FDA.
- Review the Company's most recent 10-Q or 10-K for current cash runway and burn rate, as this filing does not provide liquidity data.
- Monitor subsequent communications for any updates on the status of the additional data submission.
- Confirm the impact of the February 8, 2026, decision date on the Company's projected cash flow and financing needs.